Gilead Sciences (GILD) Capital Expenditures (2009 - 2026)

Gilead Sciences (GILD) has 18 years of Capital Expenditures data on file, last reported at $117.0 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 12.5% year-over-year to $117.0 million; the trailing twelve-month figure through Mar 2026 stood at $576.0 million (up 10.34% YoY), and the FY2025 full-year result was $563.0 million, up 7.65% from the prior year.
• Capital Expenditures for Q1 2026 stood at $117.0 million, down from $205.0 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $247.0 million in Q1 2022 and bottomed at $104.0 million in Q1 2025.
• The 5-year median for Capital Expenditures is $141.0 million (2024), against an average of $148.0 million.
• The widest annual swing landed in 2022, when Capital Expenditures soared 49.7%; it then sank 55.87% in 2023.
• A 5-year view of Capital Expenditures shows it stood at $181.0 million in 2022, then rose by 18.78% to $215.0 million in 2023, then slumped by 31.63% to $147.0 million in 2024, then jumped by 39.46% to $205.0 million in 2025, then slumped by 42.93% to $117.0 million in 2026.
• The last three Capital Expenditures figures came in at $117.0 million (Q1 2026), $205.0 million (Q4 2025), and $147.0 million (Q3 2025), per Business Quant data.

Peer Comparison